• Molecular NameGallium nitrate
  • SynonymNA
  • Weight255.735
  • Drugbank_IDDB05260
  • ACS_NO135886-70-3
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug used to treat symptomatic hypercalcemia secondary to cancer. It works by preventing the breakdown of bone through the inhibition of osteoclast activity, thus lowering the amount of free calcium in the blood.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmGallamine triethiodide is not essentially metabolized and almost 100% of the drug is excreted unchanged by kidney
  • Half life25~111 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityGallium nitrate is a poison by intraperitoneal, intravenous and subcutaneous routes, and moderately toxic by ingestion. An intravenous dose of 7 mg/kg can result in gastro-intestinal tract toxicity and 144 mg/kg in blood toxicity. It can also cause severe skin and eye irritations, at doses > 500 mg. Serious nephrotoxicity can also occur.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A